ANI Pharmaceuticals Reports Robust 2025 Growth, Unveils 2026 Financial Guidance and Strategic Roadmap

ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) announced strong preliminary financial results for full‑year 2025 and issued its full‑year 2026 financial guidance, highlighting significant growth driven by its Rare Disease business. For 2025, the company expects total net revenues between $854 million and $873 million, adjusted non‑GAAP EBITDA of $221 million to $228 million, and adjusted non‑GAAP diluted EPS of $7.37 to $7.64, all within or above previously provided guidance ranges. Its Rare Disease segment delivered exceptional performance, with Purified Cortrophin® Gel net revenues of approximately $347.8 million, up 76% year‑over‑year, and combined ILUVIEN and YUTIQ net revenues of about $74.9 million. Looking ahead to 2026, ANI projects total net revenues of $1,055 million to $1,115 million, including Cortrophin Gel revenue of $540 million to $575 million and adjusted non‑GAAP EBITDA of $275 million to $290 million. The company expects its Rare Disease business to account for roughly 60% of total net revenues. As part of its strategic priorities, ANI plans a mid‑year expansion of its Rare Disease organization by approximately 90 employees to pursue opportunities in treating acute gouty arthritis flares—an indication unique to Cortrophin Gel. The company will present these updates at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026. #ANIPharmaceuticals #RareDiseaseGrowth #2026Guidance #CortrophinGel #SlimScan #GrowthStocks #CANSLIM